EP4100530A4 - Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras - Google Patents

Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras Download PDF

Info

Publication number
EP4100530A4
EP4100530A4 EP21784308.5A EP21784308A EP4100530A4 EP 4100530 A4 EP4100530 A4 EP 4100530A4 EP 21784308 A EP21784308 A EP 21784308A EP 4100530 A4 EP4100530 A4 EP 4100530A4
Authority
EP
European Patent Office
Prior art keywords
kras
inhibition
compositions
methods
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21784308.5A
Other languages
German (de)
English (en)
Other versions
EP4100530A1 (fr
Inventor
Chad PECOT
Salma H. Azam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/842,404 external-priority patent/US11180759B2/en
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of EP4100530A1 publication Critical patent/EP4100530A1/fr
Publication of EP4100530A4 publication Critical patent/EP4100530A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP21784308.5A 2020-04-07 2021-04-07 Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras Pending EP4100530A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/842,404 US11180759B2 (en) 2016-01-19 2020-04-07 Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
PCT/US2021/026147 WO2021207339A1 (fr) 2020-04-07 2021-04-07 Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras

Publications (2)

Publication Number Publication Date
EP4100530A1 EP4100530A1 (fr) 2022-12-14
EP4100530A4 true EP4100530A4 (fr) 2024-05-22

Family

ID=78024140

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21784308.5A Pending EP4100530A4 (fr) 2020-04-07 2021-04-07 Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras

Country Status (4)

Country Link
EP (1) EP4100530A4 (fr)
JP (1) JP7839554B2 (fr)
CA (1) CA3169550A1 (fr)
WO (1) WO2021207339A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4149557A4 (fr) * 2020-05-13 2025-01-15 The University of North Carolina at Chapel Hill Conjugués de ligand lié à un acide nucléique et leur utilisation pour l'administration à des cellules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108217A2 (fr) * 2007-09-18 2009-09-03 Intradigm Corporation Compositions comprenant un arnsi de k-ras et procédés d’utilisation
WO2016201323A1 (fr) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Utilisation d'exosomes pour le traitement de maladies
WO2017173304A1 (fr) * 2016-04-01 2017-10-05 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
WO2019204624A1 (fr) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System Modulation thérapeutique de suppresseurs tumoraux à l'aide d'exosomes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103555722B (zh) * 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
EA201492004A1 (ru) * 2012-05-02 2015-08-31 Новартис Аг Органические композиции для лечения kras-ассоциированных заболеваний
WO2015164818A1 (fr) * 2014-04-25 2015-10-29 Strike Bio, Inc. Arni à cibles multiples permettant le traitement de cancers
WO2017127473A1 (fr) * 2016-01-19 2017-07-27 The University Of North Carolina At Chapel Hill Procédés et compositions utilisant l'interférence par arn pour l'inhibition de kras

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108217A2 (fr) * 2007-09-18 2009-09-03 Intradigm Corporation Compositions comprenant un arnsi de k-ras et procédés d’utilisation
WO2016201323A1 (fr) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Utilisation d'exosomes pour le traitement de maladies
WO2017173304A1 (fr) * 2016-04-01 2017-10-05 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
WO2019204624A1 (fr) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System Modulation thérapeutique de suppresseurs tumoraux à l'aide d'exosomes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. V. PECOT ET AL: "Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 12, 1 December 2014 (2014-12-01), US, pages 2876 - 2885, XP055303664, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-14-0074 *
See also references of WO2021207339A1 *

Also Published As

Publication number Publication date
JP2023521383A (ja) 2023-05-24
JP7839554B2 (ja) 2026-04-02
CA3169550A1 (fr) 2021-10-14
WO2021207339A1 (fr) 2021-10-14
EP4100530A1 (fr) 2022-12-14

Similar Documents

Publication Publication Date Title
CA3262972A1 (fr) Compositions et méthodes d'inhibition de kras
GB2605538B (en) Compositions and methods for delivery of RNA
AU2024245542A1 (en) Kras inhibitors
AU2022298774A1 (en) Antisense compounds and methods for targeting cug repeats
AU2021413753A9 (en) Compositions and methods for delivery of rna
IL304123A (en) RNA transfer preparations and methods
EP4351542A4 (fr) Méthodes de traitement de la malignité des lymphocytes b au moyen d'un inhibiteur de bcl-2
EP4100530A4 (fr) Procédés et compositions utilisant l'interférence par l'arn et des oligonucléotides antisens pour l'inhibition de kras
AU2024246572A1 (en) Antisense oligonucleotides for the treatment of liver disease
IL320984A (en) Chemically modified antisense oligonucleotides (ASOS) and compositions comprising them for RNA editing
SG10201906239RA (en) Compositions and methods for inhibition of rna editing for treatment of cancer
CA3296128A1 (fr) Oligonucléotides antisens ciblant mir-34a-5p et leurs méthodes d'utilisation
EP4067489A4 (fr) Méthode visant à réduire la toxicité d'acides nucléiques antisesns
EP4097475A4 (fr) Procédés et compositions pour l'expression d'acide nucléique impliquant l'inhibition de voies nf-kb et/ou de voies irf
CA3298803A1 (fr) Oligonucléotides antisens chimiquement modifiés (asos) et compositions pour l'édition d'arn
AU2024325709A1 (en) Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
TWI924056B (zh) Kras抑制劑的製備方法、其中間體和其中間體的製備方法
WO2024036157A9 (fr) Procédés de diminution ou d'inhibition de l'arn rétrotransposon l1 humain et compositions destinées à être utilisées dans ceux-ci
HK40115976A (en) Targeted inhibition of reverse transcription using antisense oligos
CA3266104A1 (fr) Compositions et méthodes d'administration d'arn
CA3284828A1 (fr) Agents d'arni pour inhiber l'expression de l'ataxine-2 (atxn2), compositions associées et procédés d'utilisation
CA3280428A1 (fr) Compositions et procédés d'inhibition de kras pour le traitement d'une maladie
CA3299146A1 (fr) Compositions et procédés d'inhibition de l'expression de pd-l1
CA3272746A1 (fr) Oligonucléotides antisens pour le traitement de l'hémochromatose hfe héréditaire
HK40097579A (en) Compositions and methods for inhibiting gene expression

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220907

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240125BHEP

Ipc: C12N 15/113 20100101AFI20240125BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240417BHEP

Ipc: C12N 15/113 20100101AFI20240417BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL